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Gene and immunotherapeutic approaches to treat human malignant tumors are reviewed, 
Special attention is given to the different strategies of cancer gene therapy and to recent 
aspects of cytokine-supported tumor immunotherapy or tumor-specific vaccination. The 
limitations of these therapy approaches are critically discussed especially with respect to 
immune escape mechanisms. 
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Gene therapy of cancer 
In recent years various gene therapeutic approaches to 
the treatment of human cancer have been developed 
and over 300 clinical protocols have already been 
approved. 1'2 Three main categories of somatic ell gene 
therapy can be identified. 2 First, cells are removed from 
the body or obtained from tissue culture, transfected ex 
vivo with a vector and reinfused after gene engineering 
into the patient. 3Second, the vector is placed directly in 
situ into affected tissues, eg the lung or a tumour mass, 
of the patient. 2 Third, is an in vivo therapy, whereby the 
vector is injected directly into the blood stream. At 
present here are only clinical examples of the first two 
categories. In these studies, the genes were transferred 
into target cells either by lipofection, electroporation r 
naked DNA technique using classic eukaryotic expres- 
sion vectors, eg based on SV40 or cytomegali virus 
(CMV), or viral vectors based on RNA (eg MuLV), or 
DNA viruses (eg of adeno or poxvirus families). 2
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Using these tools, gene cancer therapy tries to 
intervene at different molecular or physiological levels 
of the malignant tumour cell development. One 
approach attempts to infect cancer cells with intact 
tumour suppressor (eg p53) or anti-oncogenes, and to 
use, respectively, antisense oligonucleotides or intra- 
cellular recombinant single chain antibodies to inhibit 
activated oncogenes (eg c-myb, erbB2). 4-7 Other strate- 
gies try to modify cellular drug resistance (eg by wild 
type MDR cDNA) or to introduce 'suicide' genes, eg 
herpes simplex virus thymidine kinase (HSV-tk), into 
the tumour cells. 8'9 A further approach, especially used 
in leukaemia nd lymphoma patients, introduces gene 
markers (eg ~-galactosidase, n omycin resistance) into 
blood or bone marrow cells to identify efficacy of 
purging and origin of relapse following autologous stem 
cell transplantationJ ~ The most commonly used 
concept (64/144 clinical protocols worldwide), however, 
tries to augment the immune system's capacity to 
eliminate autologous cancer cells by different 
approaches. 
This is attempted by cytokine-supported immuno- 
therapy, enhancing the tumour immunogenicity or 
tumour-specific vaccination and by combinations of the 
different approaches (see reviews of recent clinical 
protocols 1.2). 
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Cytokine-supported 
immunotherapies 
The notion that cytokines such as interferons and 
interleukins can enhance the immunogenicity and 
induce reproducible responses also to spontaneous 
tumours led to increasing investigations and later 
clinical use. 12-14 Clinical trials were started with sys- 
temic applications of intefferons and interleukin-2 
(IL-2)) 5'16 After administration ofhigh doses of recom- 
binant IL-2 to 283 consecutive patients (Surgery 
Branch at the National Cancer Institute: 1985-1992), 
complete responses were seen in patients with meta- 
static renal cell cancer (9%) or melanoma patients 
(7%). However, systemic IL-2 administration was 
associated with substantial toxicity (eg capillary leak 
syndrome).14 These side effects, including treatment- 
related mortality, could be diminished by cardiac 
screening of patients and the aggressive use of prophy- 
lactic antibiotics, but they remain a problem) 4
The mechanism(s) by which cytokines support an 
anti-tumoural immune response are manifold) 2"L~ It 
was proposed that local rather than systemic ytokine 
effects mimic the natural cytokine physiology and are 
more likely to promote T cell responses against weak 
immunogenic tumour antigens, to activate non-specific 
killing (NK), lymphokine activated killer (LAK) cells, 
Mo/MO, or to enhance tumour antigen presentation. 
This hypothesis was supported by rejection of tumours 
after repeated local administration of exogeneous 
cytokines in the vicinity of draining lymph nodes or 
directly into the tumour] 7 In addition, numerous 
studies have shown that weakly immunogenic turnout 
cells could be altered to become targets for specific 
immune rejection by transfection with cytokine genes. 
The first experimental models and clinical applications 
carrying cytokine gene transfected malignant cells 
focused on IL-2.18-27 In most experimental systems, the 
expression of IL-2 by weakly immunogenic tumour 
cells resulted in growth inhibition of the modified 
tumour cells. In several cases, a systemic immune 
response against the parental tumour, leading to an 
immune memory against a challenge with parental 
tumour cells was also observed] 9-21 The inhibitory 
effect was dose dependent and the degree of suppres- 
sion of growth correlated irectly with the amount of 
IL-2 produced by the tumour cells. In vaccination 
experiments, however, intermediate doses of IL-2 
achieved highest cure rates in mice. 2~'29 Clinical trials 
treating advanced cancer patients with IL-2 secreting 
tumour cells showed a variable outcome of the therapy. 
Thus, tumour regression, stabilisation of the disease, 
mixed types of response with simultaneous evidence of 
regressing and non-responding lesions in the same 
patient or progressive tumour growth were noted. 3~ 33 
The evaluation of mechanisms involved in treatment 
with transfected tumour cells showed that IL-2 release 
in situ leads to a dense infiltration of the tumour 
involving mainly CD4 + and CD8 + T cells as well as NK 
cells. It was demonstrated that CD8 § T cells are 
essential for complete tumour rejection and long term 
protection against the original tumour 1934"35 and that 
IL-2 can bypass CD4 § T helper function in the 
generation of an ant i - tumour esponse ~9 or can over- 
come cytotoxic T lymphocyte (CTL) anergy. 36"37 The in 
vivo role of NK cells remains unclear but might be 
important especially in tumours with down regulated 
MHC class I molecules or in the absence of killer cell 
inhibitory receptors (K IR) .  38"39"4~ 
Several other interleukins (IL-4, IL-7, IL-12, IL-13), 
interferons (IFNy, IFNa), haematopoietic growth fac- 
tors, granulocyte-macrophage colony-stimulating fac- 
tors (GM-CSE G-CSE M-CSF), chemokines (MCP-1, 
TCA-3), and inflammatory mediators - tumour necro- 
sis factor (TNF), IL-1, IL-6 - transfected in tumour cells 
showed similar tumouricidal effects mediated by differ- 
ent effector mechanisms) 2'~ It was also demonstrated 
that cytokines can be protective against umour growth 
if transfected into normal fibroblasts or when secreted 
by allo or xenogeneic cells with respect o the tumour 
and the host animal] 3"3&42 The concept of using 
cytokine-transfected allogenic and xenogenic tumour 
cells or fibroblasts instead of autologous/syngenic cells 
in the prevention and treatment of tumours was 
developed by several groups, eg by P Kourilsky at the 
Institut Pasteur in Paris) 2 It included the transfection 
of different murine tumour cells with murine or human 
cytokines (IL-2, GM-CSF, IL-4, and IFNy) or allogenic 
major histology complex (MHC) class I molecules 
(H2-Kb). ~2"3~'43 Using allo or xenogenic cytokine- 
secreting cells, it was demonstrated that this specific 
immunotherapeutical strategy was effective to control 
tumour growth in several mouse and rat models. 12"38"43 
This anti-tumour effect was mainly mediated by 
NK-cells. 38 The results led to the initiation of a 
controlled study more closely mimicking the biology of 
human tumours. Treatment of spontaneous fibrosarco- 
mas in cats and melanomas in dogs with xenogenic IL-2 
transfected fibroblasts, the green monkey cell line 
79 
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(Vero-IL-2) (Transg~ne, Strasbourg) resulted in sub- 
stantially improved isease free and overall survival. 42 
Although many questions remain to be answered, 
and only in some experimental systems was rejection of 
established disease achieved, 42'44~9 the promising 
results obtained in animal studies have established the 
basic biological value of gene therapy with cytokine- 
secreting cells and these approaches are already widely 
used in clinical trials. 1'13 More than 60% (26/43) of 
recent 'cytokine-supported' clinical cancer gene ther- 
apy trials use IL-2, whereas others utilise IL-4, IL-7, 
IL-12, IFNy, GM-CSF, TNF or combinations thereof, t 
One of the first cancer gene therapy trials initiated in 
Switzerland in January 1996 used the 'xenogenic 
approach', t2'42 In this study, three cohorts of three 
successive patients with advanced solid tumours acces- 
sible to CT or ultrasound-guided injection were treated 
intra-tumourally repeatedly with different doses of 
xenogeneic monkey fibroblasts ecreting high doses of 
human IL-2 (Vero-IL-2). Endpoints of the study were 
feasibility, toxicity, and clinical and biological effects of 
this novel approach to immunotherapy of cancer. 
Treatment was well tolerated and toxicity consisted of 
transient fever in one patient and short-lived, mild 
itching and erythema in two others. One patient with 
soft tissue sarcoma showed a more than 90% and more 
than 50% reduction of the volume of two distant, non- 
injected metastases, lasting for 29+ and 26 months, 
respectively. Four other patients howed stabilisation of 
their disease for 3-9 months, among whom was a 
patient with melanoma who developed marked vitiligo. 
Repeated injection of up to 5 x 107 Vero-IL-2 cells was 
thus feasible and safe in heavily pretreated patients 
with advanced solid tumours and showed signs of 
clinical and biological activity. 33 Histopathological, 
immunological nd molecular analyses were performed 
on biopsy specimens of tumours and blood samples 
obtained before, during and after treatment. Only a 
slight but statistically significant (P< 0.05) increase of 
serum IL-2 could be observed on day 5 of treatment 
which returned to base line values by day 15. Also on 
day 5, a significant increase (P < 0.05) in CD3 mRNA 
was detected in tumour biopsies by RT-PCR, indicating 
transient infiltration of injected sites by T lympho- 
cytes. 33 No expression of exogenous IL-2 mRNA (ie of 
the transgene) could be detected by RT-PCR in tumour 
biopsies and peripheral blood of days 1, 5, and 15, most 
likely reflecting rapid destruction of Vero cells by 
patient's NK cell-like killer cells. 
Melanoma antigens: recognition 
and vaccination 
An important prerequisite for the induction of a 
tumour-specific immune response is the MHC 
restricted T lymphocyte r cognition 5~ of small antigenic 
peptides 5~ from tumour-specific (TSA) or tumour- 
associated (TAA) antigens in tumour cells. 52"53'54 
To identify the antigenic peptides recognised by 
tumour-specific CTL on MHC class I molecules, mainly 
four methods have been used: transfection of recombi- 
nant tumour DNA libraries into cells expressing MHC 
presenting molecules, 54 biochemical purification of 
peptides eluted from MHC molecules of the tumour 
cells, 55 designing of consensus anchor motifs carrying 
candidate peptides from proteins known to be overex- 
pressed or mutated in tumour cells 56 or screening of 
cellular immune response to SEREX-defined (sero- 
logical analysis of tumour antigens by recombinant 
cDNA expression cloning) tumour antigens. 57"58 
Based on the pattern of expression of the parent 
protein and tumour specificity, the antigens can be 
classified into five major groups: 
i) antigens resulting from mutations, 59'6~ 
ii) viral antigens, 61
iii) tumour-specific shared antigens of the 'cancer 
testis' gene family, 62'63 
iv) over expressed antigens 64"65, and 
v) tissue-specific differentiation (TSDA) 
ant igens .  53-55,66 
The number of tumour-specific mutated neoepitopes 
(eg in melanoma, renal cell cancer) or viral antigenic 
peptides (eg in cervical cancer, hepatomas) recognised 
by human CTL clones is growing continuously. 6~ 
In various cancer patients bearing the appropriate 
MHC haplotypes, however, an important number of 
CTL clones is directed against peptides from molecules 
(MAGE, BAGE, GAGE and RAGE gene family) of 
the so-called 'cancer testis' antigen group. 53'54'66 These 
peptides are able not only to stimulate CTL specific to 
melanoma cells in vitro 69-71 but also to induce tumour 
regression in vivo.  72-74 Another group of antigenic 
peptides recognised by a large number of CTL clones 
from melanoma patients 74-78 derives from TSDAs 
(Pmel-17/gp100, MART-1/Melan-A, tyrosinase, and 
tyrosinase-related proteins, TRP-1 and 2) that are also 
expressed in normal melanocytes. 79 The role of CTL 
against hese 'autoantigenes' in melanoma rejection is 
not clear. However, sometimes a depigmentation, a 
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so-called vitiligo, can be observed in treated melanoma 
patients. The observed epigmentation which is proba- 
bly caused by destruction of normal melanocytes and 
the reported association of vitiligo with prolonged 
survival and spontaneous tumour egression support a 
possible role of anti-TSDA CTL in tumour regres- 
sion. 53'54 Most of the melanoma antigenic peptides 
characterised until now are restricted to HLA-A1, 
HLA-A2 or HLA-A31 molecules, 5~54"58 expressed in 
about 26%, 44% or 6% of Caucasian melanoma 
patients, respectively. 7~'8~ Therefore, clinical applica- 
tions of antigenic peptides for tumour vaccination or 
therapy monitoring (eg by ELISPOT) are limited to 
patients of these MHC haplotypes. 69"73'74'76"81"~2 The first 
attempts to immunise melanoma patients with MAGE- 
1, MAGE-3, tyrosinase, gp-100 or MART-1 peptides 
showed objective turnout regression in a few patients. 
In some cases the clinical response was accompanied by 
the presence of peptide-specific CTL in the 
blood.  69'76'81'83'~4 A more 'MHC-independent', mela- 
noma-specific vaccination was obtained in a more 
recent  study,  73 using autologous dendritic cells (DC) 
pulsed with tumour cell extracts, supported by an 
additional 'non-specific' CD4 helper cell stimulation 
with keyhole limpet haemocyanin (KLH) which 
resulted in objective clinical responses in 5/16 patients. 
The tumour regression was accompanied by a periph- 
eral immune response, as detected by delayed-type 
hypersensitivity skin reaction to melanoma peptide or 
tumour cell lysate pulsed DCs. 7~ The application of 
somatic cell hybrids (SCH) s5 87 of syngenic or autolo- 
gous tumour cells with professional APCs (dendritic 
cells, M| or activated B-cells) 8~ has been recently 
applied in rat and mouse tumour models as another 
successful therapeutic approach for a more 'MHC- 
independent' vaccination. 85-8~ 
A third way, the combination of 'non-specific' (eg 
IL-2 supported) stimulation and specific vaccination 
(gp-100 peptide) also resulted in objective cancer 
responses but was accompanied by decreased circulat- 
ing CTL in the blood of 13/31 patients. TM This dis- 
appearance of peripheral CTL was explained by their 
possible invasion of tumour sites. In contrast o the 
other vaccination strategies, a clinical response to this 
treatment, however, was only found in those patients 
who had also received systemic IL-2, indicating syner- 
gistic effects of the two components. Together with the 
results of our phase I study, these data support our 
recently initiated randomised, French-Swiss multi- 
centre phase II trial using two different doses of Vero- 
IL-2 cells injected repeatedly in patients with 
melanoma. 
A simultaneous monitoring of the treatment seems 
to be important for understanding the mechanisms of 
different treatment strategies. Skin testing, 73 somatic 
cell hybrids 85'86 or the use of autologous antigen 
presenting cells (APC) pulsed with peptides, tumour 
extracts or infected with recombinant viruses encoding 
tumour antigens 8~~~ could become useful tools for 
monitoring peripheral anti-tumour responses to detect 
CTL precursor cells recognizing epitopes restricted to 
various MHC haptotypes in vitro. Additionally, these 
approaches also allow the detection of MHC class II 
restricted tumour antigen presentation. 84'89~9~ 
Immune escape mechanisms 
Induction and detection of T-cell response to tumour 
antigens, however, is frequently limited by the tumour 
cells themselves. Malignant transformation is often 
associated with genetic alterations providing tumour 
cells with mechanisms to escape from immune surveil- 
lance leading to selection of less immunogenic tumour 
cell variants. 9t-95 This can be observed in primary or 
metastatic tumour lesions in vivo but can also be 
detected after oncogenic transformation i  vitro. At the 
molecular level, the defective signalling of tumour cells 
could be attributed to 
i) down regulation or loss of major histocompatibil- 
ity complex (MHC) molecu les ,  96'97 
ii) alteration of antigen processing pathways, result- 
ing in an inability to present tumour-specific 
antigens to T cells, 98"99 
iii) absence of costimulatory or adhesion molecules 
that are essential for activation of the host 
immune system, J~~176 or 
iv) production of factors modifying host immune 
responses. 102 
Presentation of antigenic peptides on MHC class I or 
II molecules i essential for induction or reactivation of 
a specific immune response9 '1~ m6 Downregulation or 
loss of certain MHC haplotypes or melanoma ntigens 
enables tumour cells to escape immune surveil- 
lance, roT-m9 Therefore, an altered expression of these 
molecules might represent an important parameter 
restricting the chances of a successful gene/immune 
therapy. ~~176 However, the opposite might also be 
true. A partial human leukocyte antigen (HLA) loss 
81 
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can lead to tumour cell killing by KIR expressing CTL 
if the loss-variant downregulates respective MHC 
molecules (eg HLA-Cw7) recognised by the KIR (eg 
p58.2), whereas original tumour cells will not be lysed. 39 
The analysis of the involved mechanisms, eg [32M loss, 
'defective' expression of transporter associated with 
antigen presentation (TAP) or proteasome subu- 
nits, 94'109"u~ will also show whether eversible (eg by 
IFNy stimulation) or irreversible changes in the tumour 
cells are responsible for defective tumour antigen 
expression.94,~ 09,110.112 
Outlook 
Immune therapy is one possibility of cancer treatment. 
Since the detection of tumour-specific or associated 
antigens in spontaneous human tumours, rapidly pro- 
gressing strategies to treat cancer patients have been 
developed. Successful treatment ofpatients, however, is
furthermore narrowed by our limited understanding of 
relationships between the components of the immune 
system and tumour cells. In the case of gene therapy, in 
1996, experts of the US Department of Health, NIH, 
evaluated results of the first 7 years of treatment. In 
conclusion, they noted that gene therapy has been a 
feasible and until now also very safe treatment, but 
unequivocal proof of clinical efficacy failed in many of 
the more than 100 clinical trials. The most important 
consequence of the report was the request o 'go back 
to the bench' as well as to develop more effective viral 
and non-viral gene therapy vectors. In the meantime 
more than 300 clinical protocols with more than 3000 
patients are open worldwide but the assessment of the 
situation has not changed dramatically. The main 
problems are still the failure of vectors to transduce 
efficiently their targets in vivo, the lack of tumour 
specificity of available application systems, the increas- 
ing switch-off of transcription elements in vivo, even 
after successful transfer of the transgenes, and the 
incomplete understanding of the molecular pathology 
of tumour development and progression. 
W French Anderson, one of the pioneers of gene 
therapy expects the first unequivocal clinical results 
within the next 5 years, most probably in the field of 
genetic originative diseases. 2 In the same period the 
first tumour-specific vectors will be applied in clinical 
practice and tissue-specific expression of transgenes 
will be realised. Among others, one result of the 
terminated 'Human Genome Project' will be an expo- 
nential growth of various gene therapy studies in the 
subsequent decade. At the end of this period, the first 
intraveneous applicable vectors will be used in clinical 
practice, resulting in an efficient expression of trans- 
genes in a sufficient number of tumour ceils. When 
induction of tumour remission by gene or immune 
therapy will be possible remains peculation. Probably 
gene and/or immune therapy at most will act as part of 
a multimodal strategy in oncological therapy, combin- 
ing surgical, radiotherapeutical, cytostatical nd other 
strategies. 
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